Suppliers / Curia New York

Curia New York

United States Updated 9 July 2026

The public registers hold a second record for Curia New York. The fuller profile, with 116 active US DMFs and 8 valid CEPs, is at Curia. Figures on this page cover only this record.

Curia New York is an API manufacturer based in United States. It holds 17 active US drug master files across a filed portfolio of 13 molecules. Its most recent recorded inspection, by US FDA, closed on 5 February 2026 as OAI.

17
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
8 of 8 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 5 February 2026 OAI US FDA
  • 1 November 2023 VAI US FDA
  • 9 November 2017 VAI US FDA
  • 22 May 2015 VAI US FDA
  • 15 January 2014 VAI US FDA
  • 30 January 2013 VAI US FDA
  • 29 March 2012 NAI US FDA
  • 7 April 2010 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Rensselaer, United States 1310298

What they file, and where

Molecule Regulators Docs
Amphetamine US FDA 3
Dextroamphetamine US FDA 3
Cannabidiol US FDA 1
Echothiophate US FDA 1
Epinephrine US FDA 1
Meperidine US FDA 1
Metolazone US FDA 1
Norepinephrine US FDA 1
Pentobarbital US FDA 1
Pralidoxime US FDA 1
Show all 13 molecules on file
Racepinephrine US FDA 1
Triethylenetetramine US FDA 1
Vorinostat US FDA 1

Also appears on these molecule pages

Amphetamine API Cannabidiol API Dextroamphetamine API Epinephrine API Metolazone API Norepinephrine API Triethylenetetramine API

Questions about Curia New York

Does Curia New York hold a US DMF or a CEP?
Curia New York holds 17 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Curia New York FDA-registered?
One site operated by Curia New York carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Curia New York's last inspection go?
The most recent inspection on record closed on 5 February 2026 as OAI (Official Action Indicated, the worst classification: objectionable conditions were found and regulatory action was warranted). 8 inspections are on file, of which 1 closed as OAI.
Where does Curia New York manufacture?
1 registered site is on record, in United States (Rensselaer). Every site is listed on this page with the register it came from.
What does Curia New York make?
13 molecules are on record against Curia New York, including Amphetamine, Dextroamphetamine, Cannabidiol and Echothiophate. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Curia New York comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • 3 active litigation matters are on record.
  • The most recent inspection outcome was OAI, on 5 February 2026.

Comparable suppliers

Biophore India Pharmaceuticals shares 3 molecules Veranova Lp shares 3 molecules Cambrex Profarmaco Milano shares 2 molecules Specgx shares 2 molecules Cambrex Charles City shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability